Arrowhead Research | ARWR - Betriebsaufwand

Aktienkurs
73.91
Täglich Wechseln
-0.49 -0.66%
Monatlich
21.62%
Jährlich
457.81%
Q2 Prognose
72.33




Betriebsaufwand Veränderung Datum
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.8B 61M 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xencor USD 81.86M 13.35M 2025-12